<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="148107">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02060487</url>
  </required_header>
  <id_info>
    <org_study_id>A1481324</org_study_id>
    <nct_id>NCT02060487</nct_id>
  </id_info>
  <brief_title>Effects of Oral Sildenafil on Mortality in Adults With PAH</brief_title>
  <acronym>AFFILIATE</acronym>
  <official_title>A Multinational, Multicenter Study to Assess the Effects of Oral Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension (PAH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a blinded study in adult patients with PAH evaluating the relative effects of
      sildenafil on mortality when administered at the three doses (80 mg, 20 mg or 5 mg, all
      three times per day [TID]).  In addition, the relative effects on clinical worsening and
      6-minute walking distance (6MWD) will be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>every 3 months up to month 96</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Time in weeks from the start of study treatment to date of death due to any cause. Death will be determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first clinical worsening (TTCW) event</measure>
    <time_frame>every 3 months up to month 96</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>TTCW defined as the number of days between first dose of study drug and the occurrence of a predefined clinical worsening event. Predefined clinical worsening events include: death, hospitalization due to worsening PAH or disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 Minute Walk Distance (6MWD) at Months 6 &amp; 12</measure>
    <time_frame>Months 6 &amp; 12</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>6MWD is the distance a participant can walk in 6 minutes.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">429</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil citrate</intervention_name>
    <description>sildenafil citrate (PDE-5 inhibitor) 5 mg tablet TID until study treatment discontinued or end of study</description>
    <arm_group_label>Low dose</arm_group_label>
    <other_name>Revatio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil citrate</intervention_name>
    <description>sildenafil citrate (PDE-5 inhibitor) 20 mg tablet TID until study treatment discontinued or end of study</description>
    <arm_group_label>Medium dose</arm_group_label>
    <other_name>Revatio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil citrate</intervention_name>
    <description>sildenafil citrate (PDE-5 inhibitor) 80 mg tablet TID until study treatment discontinued or end of study</description>
    <arm_group_label>High dose</arm_group_label>
    <other_name>Revatio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects  ≥  18 years of age with any of the following conditions:

          -  Idiopathic Primary Pulmonary Arterial Hypertension (IPAH)

          -  PAH secondary to connective tissue disease

          -  PAH with surgical repair (at least 5 years previously) of atrial septal defect
             (ASD),ventricular septal defect (VSD), patent ductus arteriosus (PDA) and
             aorto-pulmonary window

          -  PAH diagnosis confirmed by right heart catheterization  performed within 12 months
             prior to randomization

          -  Functional Class II-IV;  Baseline 6MWD ≥ 50 m.

        Exclusion Criteria:

          -  Significant (ie, &gt;2+) valvular disease other than tricuspid regurgitation or
             pulmonary regurgitation

          -  History of cardiac arrest, respiratory arrest, hemodynamic collapse, CPR, ventricular
             tachycardia, ventricular fibrillation, or permanent atrial fibrillation

          -  History of pulmonary embolism; History of chronic lung disease / restrictive lung
             disease (eg, chronic obstructive pulmonary disease (COPD) or scleroderma) with
             impairment of lung function

          -  Treatment with PDE-5 inhibitors for PAH

          -  Treatment with bosentan within 3 months of randomization

          -  Current treatment with nitrates or nitric oxide
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1481324&amp;StudyName=Effects%20of%20Oral%20Sildenafil%20on%20Mortality%20in%20Adults%20with%20PAH</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>January 29, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pulmonary arterial hypertension</keyword>
  <keyword>pulmonary hypertension</keyword>
  <keyword>PAH</keyword>
  <keyword>sildenafil</keyword>
  <keyword>revatio</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sildenafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
